Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
NCT07250633
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Severe Hepatic Impairment
Normal Hepatic Function
Interventions
DRUG:
Vorasidenib 20mg
Sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)